ライフサイエンスコーパス: aspartate aminotransferase

1 ties (grade 3 diarrhoea and grade 3 elevated aspartate aminotransferase).

2 eased levels of alanine aminotransferase and aspartate aminotransferase.

3 serum levels of alanine aminotransferase and aspartate aminotransferase.

4 and eosin quantification, and serum alanine/aspartate aminotransferase.

5 ABDC active site is very similar to that of aspartate aminotransferase.

6 elevated serum alanine aminotransferase and aspartate aminotransferase.

7 n the various strata of intact PTH and serum aspartate aminotransferase.

8 ble the "open" and "closed" conformations of aspartate aminotransferase.

9 ably due to the high K(m) of the cytoplasmic aspartate aminotransferase.

10 us co factor for diverse enzymes, among them aspartate aminotransferase.

11 hydrogenase < 100 U/L, below analyzer range; aspartate aminotransferase 0 hour, 15.6 +/- 9.3 U/L vs 7

12 the role of endogenous sulfur dioxide (SO2)/ aspartate aminotransferase 1 (AAT1) pathway in stretch-i

13 573 patients vs six [1%] of 570), increased aspartate aminotransferase (103 [18%] vs 16 [3%]), hyper

14 e (15%), alanine aminotransferase (12%), and aspartate aminotransferase (11%).

15 dL), alanine aminotransferase (2288.82 U/L), aspartate aminotransferase (1251.76 U/L), gamma-glutamyl

16 %] of 573 vs one [<1%] of 570) and increased aspartate aminotransferase (14 [2%] vs one [<1%]).

17 enzymes (alanine aminotransferase, 657 U/L, aspartate aminotransferase, 1401 U/L), blood urea (53 mg

18 l thromboplastin time (8% and 18%); elevated aspartate aminotransferase (15% and 18%), alanine aminot

19 lanine aminotransferase compared to group B (aspartate aminotransferase, 168[166] vs. 57[67] IU/L; P=

20 vs six [0.9%]), and reversible increases in aspartate aminotransferase (22 [3.4%] vs three [0.5%]).

21 sterol, 42.80 mg/dL (39.84-45.76 mg/dL); for aspartate aminotransferase, 22.67 U/L (19.94-25.41 U/L);

22 s of hypertension (35% vs. 15%) and elevated aspartate aminotransferase (23% vs. 8%) were higher with

23 ted with significantly lower serum levels of aspartate aminotransferase (240+/-98 IU/L vs. 382+/-163

24 ransferase (73 [30%] patients) and increased aspartate aminotransferase (25 [10%]).

25 nd elevations in alanine aminotransferase or aspartate aminotransferase (25 [12%]).

26 ed with -7.29 (-9.5, -5.1) IU/L; P < 0.001], aspartate aminotransferase [-31.33 (-32.1, -30.5) compar

27 group, SG induced significant improvement in aspartate aminotransferase (32.4 +/- 17.4 vs 21.5 +/- 6.

28 288 patients vs four [3%] of 140), elevated aspartate aminotransferase (51 [18%] vs four [3%]), hype

29 mia (86 [34%]), fatigue (83 [33%]), elevated aspartate aminotransferase (65 [26%]), and increased ala

30 0 IU/L alanine aminotransferase and 420 IU/L aspartate aminotransferase 9 hours after gavage.

31 Importantly, increasing peak perioperative aspartate aminotransferase, a surrogate marker of hepati

32 Consistently, inhibition of aspartate-aminotransferase, a key enzyme of the shunt, i

33 y crystal structure of E1, which exhibits an aspartate aminotransferase (AAT) fold.

34 In aspartate aminotransferase (AAT), an extended hydrogen b

35 SO2 synthase aspartate aminotransferase (AAT1 and AAT2) mRNA and prot

36 nalysis (fibrosis, alanine aminotransferase, aspartate aminotransferase, age, biopsy length).

37 ed plasma glucose, alanine aminotransferase, aspartate aminotransferase, AGEs and insulin levels.

38 ur algorithm included data on age; levels of aspartate aminotransferase, alanine aminotransferase (AL

39 aspartate aminotransferase, alanine aminotransferase (AL

40 creatinine (indicator of renal dysfunction), aspartate aminotransferase, alanine aminotransferase (ma

41 of serum liver tests (alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase) an

42 (international normalized ratio, bilirubin, aspartate aminotransferase, alanine aminotransferase) an

43 m injury by reducing the activities of serum aspartate aminotransferase, alanine aminotransferase, an

44 of hepatocyte injury and cholestasis (serum aspartate aminotransferase, alanine aminotransferase, bi

45 ic diagnoses and laboratory values (albumin, aspartate aminotransferase, alanine aminotransferase, cr

46 o routine markers of liver impairment (e.g., aspartate aminotransferase, alanine aminotransferase, la

47 Mean aspartate aminotransferase, alanine aminotransferase, to

48 is and a substantially higher AUROC than the aspartate aminotransferase-alanine aminotransferase rati

49 occur in previous studies showing increased aspartate aminotransferase-alanine aminotransferase rati

50 ly improved liver function assessed by serum aspartate aminotransferase/alanine aminotransferase leve

51 on age, viral genotype, initial viral load, aspartate aminotransferase/alanine aminotransferase rati

52 outcome in multivariate analyses were higher aspartate aminotransferase/alanine aminotransferase rati

53 s the elevation in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and ga

54 rtal areas in the biopsy, patient age, serum aspartate aminotransferase, alkaline phosphatase, and pl

55 trition and inflammation, minerals, PTH, and aspartate aminotransferase, AlkPhos > or =120 U/L was as

56 olesterol, whereas increasing plasma alanine/aspartate aminotransferases (ALT/AST) and hepatic trigly

57 ociated with liver-related complications; an aspartate aminotransferase/ALT ratio >1 and older age we

58 higher mean [+/-2 standard deviation] serum aspartate aminotransferase and alanine aminotransferase

59 ma and liver triglyceride content and plasma aspartate aminotransferase and alanine aminotransferase

60 ce exhibited earlier mortality, higher serum aspartate aminotransferase and alanine aminotransferase

61 ed NASH as reflected by reductions in plasma aspartate aminotransferase and alanine aminotransferase

62 ose-limiting toxicity (one grade 3 increased aspartate aminotransferase and alanine aminotransferase

63 ing induction (20 [54%] patients), increased aspartate aminotransferase and alanine aminotransferase

64 r, and skeletal muscle and had higher plasma aspartate aminotransferase and alanine aminotransferase,

65 score created from the platelet count, serum aspartate aminotransferase and alanine aminotransferase,

66 ed in hepatic steatosis and increased plasma aspartate aminotransferase and alanine aminotransferase.

67 pect to sex, age, duration of disease, serum aspartate aminotransferase and alkaline phosphatase leve

68 During therapy, aspartate aminotransferase and alkaline phosphatase leve

69 proportion of patients alanine transaminase, aspartate aminotransferase and AlkPhos >5x upper-limit-o

70 sis, decreased platelet count, and increased aspartate aminotransferase and alpha-fetoprotein levels

71 Similarities have been discovered between aspartate aminotransferase and citrate synthase that onl

72 cyte population, depleted KCs, and increased aspartate aminotransferase and creatine kinase serum enz

73 learance of several serum enzymes, including aspartate aminotransferase and creatine kinase, that are

74 ture, decreased apoptosis, and reduced serum aspartate aminotransferase and creatinine levels compare

75 tients; one patient had grade 3 increases in aspartate aminotransferase and gammaglutamyltransferase

76 Aspartate aminotransferase and lactate dehydrogenase as

77 cally by transamination to oxaloacetate with aspartate aminotransferase and then decarboxylation with

78 yde-3-phosphate dehydrogenase, aldolase, and aspartate aminotransferase and thus reactivates these pr

79 f serum transaminases (alanine transaminase, aspartate aminotransferase) and coagulation times (proth

80 e 3 increase of alanine aminotransferase and aspartate aminotransferase) and two (13%) patients given

81 (current hematocrit, albumin, total protein, aspartate aminotransferase), and baseline demographics a

82 r injury (serum alanine aminotransferase and aspartate aminotransferase), and circulatory failure (hy

83 by IP as measured by lactate dehydrogenase, aspartate aminotransferase, and alanine aminotransferase

84 e enzyme levels (P<0.05 for creatine kinase, aspartate aminotransferase, and aldolase) and inversely

85 chemistries, including alkaline phosphatase, aspartate aminotransferase, and bilirubin, were signific

86 and elevated levels of blood urea nitrogen, aspartate aminotransferase, and creatinine.

87 as MCV and hemoglobin, alkaline phosphatase, aspartate aminotransferase, and direct bilirubin concent

88 speptidase, maximum alanine aminotransferase/aspartate aminotransferase, and fibrosis stage were asso

89 jury were measured: Plasma urea, creatinine, aspartate aminotransferase, and histology.

90 increases in alanine aminotransferase and in aspartate aminotransferase, and hyponatraemia, each occu

91 and liver enzymes (alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase) w

92 rboxylase NAD-ME, a mitochondrial isoform of aspartate aminotransferase, and photorespiratory markers

93 els of lactate dehydrogenase, bilirubin, and aspartate aminotransferase; and higher reticulocyte, whi

94 vate carboxylase, alanine, and an isoform of aspartate aminotransferase are localized in the cytosol.

95 reticulocytes, bilirubin, plasma hemoglobin, aspartate aminotransferase, arginase, and soluble adhesi

96 d predictive clinical variables and revealed aspartate aminotransferase as an important, albeit previ

97 ctivity of PLP in both GabR and a homologous aspartate aminotransferase (Asp-AT) from Escherichia col

98 nternal aldimine in alanine racemase (AlaR), aspartate aminotransferase (AspAT), and poly-L-lysine.

99 ansferases (PPA-ATs) that belong to class-Ib aspartate aminotransferases (AspAT Ibs) and catalyze the

100 ctive pulmonary disease, history of syncope, aspartate aminotransferase (AST) >600 U/L, direct biliru

101 of NASH in elderly patients included higher aspartate aminotransferase (AST) (odds ratio [OR] = 1.12

102 with both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (P < 0.0001, analysis o

103 h K8/18/Ub foci (r(2) = 0.47, P < 0.001) and aspartate aminotransferase (AST) (r(2) = 0.15, P = 0.002

104 ysophosphatidylcholines were associated with aspartate aminotransferase (AST) 14-day post-transplanta

105 Aspartate aminotransferase (AST) activity at LT (hazard

106 ity is elevated significantly by 30% whereas aspartate aminotransferase (AST) activity remains unchan

107 Aspartate aminotransferase (AST) and alanine aminotransf

108 Serum aminotransferase [such as aspartate aminotransferase (AST) and alanine aminotransf

109 In acute cases, aspartate aminotransferase (AST) and ALT were both eleva

110 Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and fetuin-A were deter

111 The increase of aspartate aminotransferase (AST) by >25% (hazard ratio [

112 ed by pure fructose) increases liver fat and aspartate aminotransferase (AST) concentrations in healt

113 eiver operating characteristics curve showed aspartate aminotransferase (AST) had highest area under

114 Liver function tests showed higher levels of aspartate aminotransferase (AST) in blood samples from p

115 minases, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) increased in all mice i

116 nal logistic regression analysis, increasing aspartate aminotransferase (AST) level (odds ratio [OR],

117 of vomiting, lower platelet count, elevated aspartate aminotransferase (AST) level, positivity in th

118 Nine studies evaluated associations between aspartate aminotransferase (AST) levels and T2D risk, wi

119 ibrosis in these patients were defined using aspartate aminotransferase (AST) levels, fibrosis-4 (FIB

120 the lower alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, less liver dama

121 fibrosis score determined by FibroSURE with aspartate aminotransferase (AST) measurements and HIV co

122 ith INH had asymptomatic, mild elevations of aspartate aminotransferase (AST) or alanine aminotransfe

123 ension with grade 3 rash and fevers, grade 4 aspartate aminotransferase (AST) or alanine aminotransfe

124 The primary endpoint was postoperative aspartate aminotransferase (AST) peak value; early graft

125 163-HCV-FS was significantly superior to the aspartate aminotransferase (AST) to platelet ratio index

126 Serum aspartate aminotransferase (AST) was higher after CCl(4)

127 nd plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were increased in wildt

128 The serum levels of aspartate aminotransferase (AST), alanine aminotransfera

129 induced Liver Damage (MALD) uses a patient's aspartate aminotransferase (AST), alanine aminotransfera

130 injury was assessed by the levels of plasma aspartate aminotransferase (AST), alanine aminotransfera

131 ated measurements (mean, 17.5 days apart) of aspartate aminotransferase (AST), alanine aminotransfera

132 Liver injury measured by aspartate aminotransferase (AST), alanine aminotransfera

133 um levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (

134 ses in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (

135 e (GGT), alanine aminotransferase (ALT), and aspartate aminotransferase (AST), among a discovery set

136 d nephropathy with alanine aminotransferase, aspartate aminotransferase (AST), and bilirubin levels <

137 sts, such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltran

138 Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltran

139 Plasma alanine aminotransferase (ALT), aspartate aminotransferase (AST), and histopathology sho

140 Transplant albumin, day-1 aspartate aminotransferase (AST), day-1 lactate, day-3 b

141 ate dehydrogenase, alanine aminotransferase, aspartate aminotransferase (AST), gamma-glutamyltransfer

142 s, increased alanine aminotransferase (ALT), aspartate aminotransferase (AST), nonsterified fatty aci

143 iabetes, hypertension, hypertriglyceridemia, aspartate aminotransferase (AST), platelets, and the hom

144 Aspartate aminotransferase (AST)-to-platelet ratio (APRI

145 We evaluated the diagnostic accuracy of aspartate aminotransferase (AST)-to-platelet ratio index

146 less severe steatosis on biopsy, lower serum aspartate aminotransferase (AST)/alanine aminotransferas

147 gression identified mean corpuscular volume, aspartate aminotransferase (AST)/alanine aminotransferas

148 sex, high levels of TBL, and a high ratio of aspartate aminotransferase (AST):ALT were independent ri

149 aminotransferase (42 versus 27, P = 0.005), aspartate aminotransferase (AST; 26 versus 21, P = 0.01)

150 etween both eprotirome groups and placebo in aspartate aminotransferase (AST; p<0.0001), alanine amin

151 ng semiannual follow-up with LFTs, including aspartate-aminotransferase (AST), alanine aminotransfera

152 Plasma aminotransferases (aspartate aminotransferase [AST] and alanine aminotransf

153 es (e.g., alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) were compared between

154 ver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyl transpe

155 Our analysis sought to validate APRI (aspartate aminotransferase [AST]-to-platelet ratio index

156 Four variables (platelet count, aspartate aminotransferase [AST]/alanine aminotransferas

157 antly superior to biochemical markers (e.g., aspartate aminotransferase [AST]/platelet ratio, FIB-4,

158 atelet ratio (APRI) was calculated as = 100*(aspartate aminotransferase [AST]/upper limit of AST)/pla

159 te aminotransferase-to-platelet ratio index (aspartate aminotransferase [AST]: platelet index), AST:a

160 ver function (alkaline phosphatase, ALP, and aspartate aminotransferase, AST) and total serum protein

161 FT abnormality was defined as an increase in aspartate aminotransferase, (AST), alanine aminotransfer

162 (SD) decreases for alanine transaminase and aspartate aminotransferase at week 12 compared to the ba

163 l, the G allele was associated directly with aspartate aminotransferase (beta = 2.60; 95% CI: 0.99, 4

164 Alanine aminotransferase, aspartate aminotransferase, BMI, insulin, Quantitative I

165 ificantly higher in group 2, conversely mean aspartate aminotransferase, cholinesterases, and prothro

166 aminotransferase and a 3.5-fold reduction in aspartate aminotransferase) compared with WT littermates

167 progression (18 [6%] vs 11 [4%]), increased aspartate aminotransferase concentration (15 [5%] vs 23

168 ration (24 [21%] vs one [1%]), and increased aspartate aminotransferase concentration (16 [14%] vs on

169 [19%] vs one [1%]) and increased alanine or aspartate aminotransferase concentration (39 [10%] vs no

170 in serum triglycerides (eight patients) and aspartate aminotransferase concentrations (two patients)

171 Elevated alanine and aspartate aminotransferase concentrations and profound e

172 weight, height, alanine aminotransferase or aspartate aminotransferase concentrations, or alcohol us

173 lel biochemical pathways, namely alanine and aspartate aminotransferases, could not compensate for th

174 Serum creatinine, serum aspartate aminotransferase, creatinine clearance, fracti

175 ate that levels of alanine aminotransferase, aspartate aminotransferase, creatinine, lactate, tumor n

176 y decreased serum levels of both alanine and aspartate aminotransferases, decreased hepatic necrosis,

177 cificity of three aminotransferases (E. coli aspartate aminotransferase, E. coli branched-chain amino

178 the apo form of homodimeric Escherichia coli aspartate aminotransferase (eAATase) (molecular mass = 4

179 ed unfolding pathway of the Escherichia coli aspartate aminotransferase (eAATase) homodimer proceeds

180 ons in the stability of the Escherichia coli aspartate aminotransferase (eAATase) homodimer was inves

181 Several mutant Escherichia coli aspartate aminotransferases (eAATases) have been charact

182 .5%) and reversible alanine aminotransferase/aspartate aminotransferase elevations (13.4%).

183 ded neutropenia, thrombocytopenia, increased aspartate aminotransferase, febrile neutropenia, and tum

184 re of NtdA shows that NtdA shares the common aspartate aminotransferase fold (Type 1) with residues f

185 aminotransferase (five [6%]), and increased aspartate aminotransferase (four [5%]).

186 A broad-specificity class V aspartate aminotransferase from M. jannaschii converted

187 aline phosphatase; alanine aminotransferase; aspartate aminotransferase; gamma-glutamyltransferase; a

188 can be confounded in the setting of abnormal aspartate aminotransferase, gammaglutamyl transpeptidase

189 Increased aspartate aminotransferase, gammaglutamyl transpeptidase

190 The aspartate aminotransferase gene AAT1 was found to be a c

191 t of a signal transduction pathway involving aspartate aminotransferase, Gln synthetase, and Asn synt

192 linked to the tricarboxylic acid cycle (eg, aspartate aminotransferase [Got2] and hydroxyacid-oxoaci

193 r Hy's criteria (alanine aminotransferase or aspartate aminotransferase greater than three times the

194 utive elevations of alanine aminotransferase/aspartate aminotransferase > or =3 times upper limit of

195 A vasopressor requirement (4 points), aspartate aminotransferase > or =80 IU/l (2 points), bil

196 nd/or levels of alanine aminotransferase and aspartate aminotransferase >30 mU/L, using magnetic reso

197 Histologic features, plasma aspartate aminotransferase, hepatic cytokine profile, ox

198 Seventy-two hrs after reperfusion, plasma aspartate aminotransferase, hepatic oxidative stress, me

199 ated levels of lactate dehydrogenase in 82%, aspartate aminotransferase in 70%, alanine aminotransfer

200 e in two patients at 20 mg/kg, and increased aspartate aminotransferase in one patient at 1 mg/kg, an

201 Median peak aspartate aminotransferase in the first 7 days was signi

202 with liver edema and raised plasma levels of aspartate aminotransferase in TRPV1 KO mice.

203 otransferase in two (8%) patients, increased aspartate aminotransferase in two (8%) patients, decreas

204 apoptosis, and activity of serum alanine and aspartate aminotransferases in wild-type mice.

205 (in 12%), alkaline phosphatase (in 21%), and aspartate aminotransferase (in 27%).

206 increase (five [14%]), pyrexia (four [11%]), aspartate aminotransferase increase (three [8%]), and ej

207 reated patients, with pneumonitis, increased aspartate aminotransferase, increased alanine aminotrans

208 dysfunction), alanine aminotransferase, and aspartate aminotransferase (indicators of liver injury)

209 Conversion of aspartate aminotransferase into tyrosine aminotransferas

210 ex, elevated serum alanine aminotransferase, aspartate aminotransferase, iron, transferrin-iron satur

211 roducible rise in liver enzymes (alanine and aspartate aminotransferases) is observed in 1 to 3% of p

212 GTK/KAT I and aspartate aminotransferase/KAT IV possess cysteine S-con

213 TA) was cocrystallized with Escherichia coli aspartate aminotransferase (l-AspAT) at a series of pH v

214 For instance, l-aspartate aminotransferase (l-AspAT) is inactivated by 4

215 liver enzymes (alanine aminotransferase and aspartate aminotransferase), lactate, albumin, and tumor

216 enzymes (i.e., alanine aminotransferase and aspartate aminotransferase), lactate, creatinine, proinf

217 Aspartate aminotransferase, lactate dehydrogenase, and a

218 ants, primarily those with a higher ratio of aspartate aminotransferase level to platelet count.

219 hrombocytopenia (70 [14%] of 490), increased aspartate aminotransferase levels (22 [5%]), and anaemia

220 inotransferase levels as it decreased plasma aspartate aminotransferase levels (by 40% vs. 21%, P=0.0

221 s also showed a significant correlation with aspartate aminotransferase levels (rs = 0.35; P = 0.02).

222 demonstrated by decreased serum alanine and aspartate aminotransferase levels and numbers of TUNEL-p

223 eight and serum alanine aminotransferase and aspartate aminotransferase levels at week 24 (P < 0.05).

224 Aspartate aminotransferase levels were found to be assoc

225 Serum alanine and aspartate aminotransferase levels were reduced with vita

226 Serum aspartate aminotransferase levels were the only clinical

227 mice with recombinant IL-22 decreased serum aspartate aminotransferase levels, ameliorated cardinal

228 y reduced serum alanine aminotransferase and aspartate aminotransferase levels, and by H&E staining.

229 A levels, serum alanine aminotransferase and aspartate aminotransferase levels, and hepatic inflammat

230 independently associated with HBV DNA load, aspartate aminotransferase levels, and platelet counts;

231 inotransferase levels, four (33%) had raised aspartate aminotransferase levels, and two (17%) had inc

232 se rates, serum alanine aminotransferase and aspartate aminotransferase levels, or longitudinal chang

233 ld higher serum alanine aminotransferase and aspartate aminotransferase levels.

234 levated baseline alanine aminotransferase or aspartate aminotransferase levels.

235 ed with improved hepatic histology and serum aspartate aminotransferase levels.

236 elevated serum alanine aminotransferase and aspartate aminotransferase levels.

237 The screen yielded GOT1, the cytosolic aspartate aminotransferase, loss of which kills cells up

238 increases (40% alanine aminotransferase, 17% aspartate aminotransferase), maculopapular rash (17%), a

239 rane fatty acid transporter as mitochondrial aspartate aminotransferase (mAsp-AT) indicated that the

240 PLP-dependent mitochondrial aspartate aminotransferase (mitAspAT) is a mitochondrial

241 creatine phosphokinase (n=2), and increased aspartate aminotransferase (n=2) each occurring in more

242 commonly reversible increases in alanine or aspartate aminotransferase) occurred in six (3%), two (1

243 nine aminotransferase of 63.9%, P<0.005; and aspartate aminotransferase of 45.0%, P<0.005) and increa

244 Minimal parenchymal damage (aspartate aminotransferase) of the liver was seen after

245 e round of DNA back-shuffling with wild-type aspartate aminotransferase on this variant generated mut

246 placebo 18.2%; p = 0.355) or adverse events (aspartate aminotransferase or alanine aminotransferase >

247 xclusion criteria were other liver diseases, aspartate aminotransferase or alanine aminotransferase c

248 grade 3-4 increases in levels of alanine or aspartate aminotransferases or bilirubin; there were no

249 ed concentrations of asymptomatic alanine or aspartate aminotransferase, or gamma-glutamyltransferase

250 h markers of hepatic inflammation (P=.02 for aspartate aminotransferase, P=.002 for ferritin) and fib

251 sis, the platelet count, age-platelet index, aspartate aminotransferase-platelet ratio index (APRI),

252 Based on aspartate aminotransferase/platelet ratio index and FIB-

253 luronic acid measurement but superior to the aspartate aminotransferase/platelet ratio index, FIB-4 s

254 or 2 of the following: NAFLD fibrosis score, aspartate aminotransferase/platelet ratio index, FIB-4 s

255 3) and 20.9 (95% CI: 2.6-165.3) based on the aspartate aminotransferase/platelet ratio index; and 6.2

256 For example, aspartate aminotransferase protonates the pyridine nitro

257 na that control the electronic modulation in aspartate aminotransferase.Pyridoxal 5'-phosphate (PLP)

258 imit the availability of oxaloacetate to the aspartate aminotransferase reaction, an important route

259 /- 77 U/L in the placebo group; P = .02) and aspartate aminotransferase (reduction, 31 +/- 52 vs 4 +/

260 Moreover, cellular injury demonstrated by aspartate aminotransferase release and cell death is les

261 oadipate aminotransferase, and mitochondrial aspartate aminotransferase, respectively.

262 nd AAT2 encoding mitochondrial and cytosolic aspartate aminotransferases, respectively; (iii) MDH1 an

263 erapy, based on alanine aminotransferase and aspartate aminotransferase response criteria, and more l

264 ic activity was associated with higher serum aspartate aminotransferase, rs12979860 IL28B genotype, a

265 (affecting >/=2% of patients) were elevated aspartate aminotransferase (six [2%] vs none), dyspnoea

266 seven [7%]), and increased concentration of aspartate aminotransferase (six [3%] vs two [2%]).

267 l homology with members of the PLP-dependent aspartate aminotransferase subfamily.

268 old types of pyridoxal phosphate enzymes: an aspartate aminotransferase subgroup 1beta in tested alph

269 osphate (PLP) dependent enzymes known as the aspartate aminotransferase superfamily or alpha-family.

270 l fold places it into the well-characterized aspartate aminotransferase superfamily.

271 tures place them into the well-characterized aspartate aminotransferase superfamily.

272 enzyme places it into the well-characterized aspartate aminotransferase superfamily.

273 e enzyme is PLP-dependent and belongs to the aspartate aminotransferase superfamily.

274 ethnicity, sex, alcohol, cirrhosis, ratio of aspartate aminotransferase to alanine aminotransferase,

275 h the inactive K258A mutant of PLP-dependent aspartate aminotransferase to give a stable external ald

276 of 3-year liver stiffness measurement (LSM), aspartate aminotransferase to platelet ratio index (APRI

277 mined by the NAFLD fibrosis score (NFS), the aspartate aminotransferase to platelet ratio index (APRI

278 f liver disease, fibrosis-4 (FIB-4), and the aspartate aminotransferase to platelet ratio index (APRI

279 luated the utility of two simple biomarkers, aspartate aminotransferase to platelet ratio index (APRI

280 level >/=3 times the upper limit of normal, aspartate aminotransferase to platelet ratio index score

281 kin 28B genotype, negatively associated with aspartate aminotransferase-to platelet ratio index, and

282 OMA-IR) and liver fibrosis defined using the aspartate aminotransferase-to-platelet ratio index (APRI

283 We used the aspartate aminotransferase-to-platelet ratio index (APRI

284 m (BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet ratio index (APRI

285 Liver fibrosis was predicted using the aspartate aminotransferase-to-platelet ratio index (APRI

286 ld vs. nonmild), defining mild disease as an aspartate aminotransferase-to-platelet ratio index (APRI

287 tic resonance imaging and MRE, FIBROSpectII, aspartate aminotransferase-to-platelet ratio index (aspa

288 ore than or equal to stage 1 groups, whereas aspartate aminotransferase-to-platelet ratio index and A

289 , liver function test, complete blood count, aspartate aminotransferase-to-platelet ratio index and t

290 edictive values of blood markers [FibroSURE, aspartate aminotransferase-to-platelet-ratio index (APRI

291 This consists of an aspartate aminotransferase (TvAspAT1), which transaminat

292 [5%]) and increased concentrations of serum aspartate aminotransferase (two [10%]) in cohort B.

293 10%]), and increased concentrations of serum aspartate aminotransferase (two [10%]).

294 Aspartate aminotransferase was significantly higher in D

295 Serum alanine aminotransferase and aspartate aminotransferase were increased by all three c

296 lar injury markers lactate dehydrogenase and aspartate aminotransferase were persistently low (lactat

297 Serum levels of both alanine and aspartate aminotransferases were also lower after intrap

298 d both the elevation in plasma IFN-gamma and aspartate aminotransferase, whereas depletion of CD8(+)

299 igher levels of alanine aminotransferase and aspartate aminotransferase, whereas the diagnosis of SH

300 cture of a homodimeric PLP-dependent enzyme, aspartate aminotransferase, which was reacted in situ wi